Vaccine-induced protection against anthrax in cheetah (Acinonyx jubatus) and black rhinoceros (Diceros bicornis).
Institution of a policy of vaccination in endangered species with a vaccine not previously administered to it cannot be undertaken lightly. This applies even more in the case of cheetah (Acinonyx jubatus) with their unusually monomorphic gene pool and the potential restrictions this places on their immune responses. However, the recently observed mortalities from anthrax in these animals in the Etosha National Park, Namibia, made it imperative to evaluate vaccination. Black rhinoceros (Diceros bicornis), another endangered species in the park, have been vaccinated for over three decades but the effectiveness of this has never been evaluated. Passive protection tests in A/J mice using sera from 12 cheetahs together with enzyme immunoassay indicated that cheetah are able to mount seemingly normal primary and secondary humoral immune responses to the Sterne 34F2 live spore livestock vaccine. Overall protection rates in mice injected with the sera rose and fell in concert with rises and declines in antibody titres, although fine analysis showed that the correlation between titre and protection was complex. Once a high level of protection (96% of mice 1 month after a second booster in the cheetahs) had been achieved, the duration of substantial protection appeared good (60% of the mice 5 months after the second booster). Protection conferred on mice by sera from three of four vaccinated rhino was almost complete, but, obscurely, none of the mice receiving serum from the fourth rhino were protected. Sera from three park lions with naturally acquired high antibody titres, included as controls, also conferred high levels of protection. For the purposes of wildlife management, the conclusions were that vaccination of cheetah with the standard animal anthrax vaccine causes no observable ill effect in the animals and does appear to confer protective immunity. At least one well-separated booster does appear to be desirable. Vaccination of rhino also appears to be justified from the limited data obtained.
Turnbull
P C B
PC
Arjemptur Technology, Science Park, Dstl, Porton Down, Salisbury SP4 0JQ, UK. peterturnbull@tesco.net
Tindall
B W
BW
Coetzee
J D
JD
Conradie
C M
CM
Bull
R L
RL
Lindeque
P M
PM
Huebschle
O J B
OJ
D002612:Acinonyx / Q000276:immunology*; D000818:Animals; D000881:Anthrax / Q000517:prevention & control* / Q000662:veterinary*; D022122:Anthrax Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000032:analysis / Q000096:biosynthesis / Q000627:therapeutic use; D001188:Artiodactyla / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007116:Immunization, Passive; D008297:Male; D051379:Mice
D022122:Anthrax Vaccines; D000907:Antibodies, Bacterial